DongKook Pharmaceutical Co., Ltd. (086450.KQ)
KRW 15310.0
(-1.73%)
KRW 15310.0
(-1.73%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 18.74 Billion KRW | -25.0% |
| 2022 | 24.99 Billion KRW | 150.0% |
| 2021 | 10 Billion KRW | -79.59% |
| 2020 | 49 Billion KRW | 17.51% |
| 2019 | 41.7 Billion KRW | 3.94% |
| 2018 | 40.11 Billion KRW | 11046.3% |
| 2017 | 359.94 Million KRW | -25.32% |
| 2016 | 482 Million KRW | -67.53% |
| 2015 | 1.48 Billion KRW | -7.36% |
| 2014 | 1.6 Billion KRW | 128.93% |
| 2013 | 700 Million KRW | 0.0% |
| 2012 | - KRW | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 15.84 Billion KRW | -4.92% |
| 2024 Q1 | 16.66 Billion KRW | -11.11% |
| 2023 Q3 | 24.99 Billion KRW | -0.0% |
| 2023 Q4 | 18.74 Billion KRW | -25.0% |
| 2023 FY | 18.74 Billion KRW | -25.0% |
| 2023 Q1 | 25 Billion KRW | 0.0% |
| 2023 Q2 | 24.99 Billion KRW | -0.0% |
| 2022 Q1 | 37.5 Billion KRW | 275.0% |
| 2022 Q3 | 19.99 Billion KRW | -0.0% |
| 2022 Q2 | 20 Billion KRW | -46.67% |
| 2022 FY | 24.99 Billion KRW | 150.0% |
| 2022 Q4 | 24.99 Billion KRW | 25.0% |
| 2021 Q4 | 10 Billion KRW | -85.4% |
| 2021 Q1 | 49.99 Billion KRW | -4.06% |
| 2021 FY | 10 Billion KRW | -79.59% |
| 2021 Q2 | 65.09 Billion KRW | 30.2% |
| 2021 Q3 | 68.5 Billion KRW | 5.22% |
| 2020 Q4 | 52.11 Billion KRW | 10.81% |
| 2020 Q3 | 47.03 Billion KRW | -30.7% |
| 2020 FY | 49 Billion KRW | 17.51% |
| 2020 Q1 | 42.8 Billion KRW | -0.92% |
| 2020 Q2 | 67.86 Billion KRW | 58.55% |
| 2019 Q4 | 43.19 Billion KRW | -21.02% |
| 2019 Q1 | 41.8 Billion KRW | 4.21% |
| 2019 Q2 | 41.76 Billion KRW | -0.1% |
| 2019 Q3 | 54.69 Billion KRW | 30.94% |
| 2019 FY | 41.7 Billion KRW | 3.94% |
| 2018 Q2 | 239.96 Million KRW | -33.33% |
| 2018 FY | 40.11 Billion KRW | 11046.3% |
| 2018 Q4 | 40.11 Billion KRW | 16619.44% |
| 2018 Q3 | 239.96 Million KRW | 0.0% |
| 2018 Q1 | 359.94 Million KRW | 0.0% |
| 2017 Q4 | 359.94 Million KRW | -53.84% |
| 2017 FY | 359.94 Million KRW | -25.32% |
| 2017 Q1 | 482 Million KRW | 0.0% |
| 2017 Q2 | 412 Million KRW | -14.52% |
| 2017 Q3 | 779.7 Million KRW | 89.25% |
| 2016 Q2 | 1.12 Billion KRW | -13.11% |
| 2016 FY | 482 Million KRW | -67.53% |
| 2016 Q1 | 1.29 Billion KRW | -12.63% |
| 2016 Q3 | 949.5 Million KRW | -15.75% |
| 2016 Q4 | 482 Million KRW | -49.24% |
| 2015 Q2 | 1.6 Billion KRW | 0.0% |
| 2015 FY | 1.48 Billion KRW | -7.36% |
| 2015 Q3 | 1.81 Billion KRW | 13.48% |
| 2015 Q1 | 1.6 Billion KRW | 0.0% |
| 2015 Q4 | 1.48 Billion KRW | -18.37% |
| 2014 FY | 1.6 Billion KRW | 128.93% |
| 2014 Q1 | 700 Million KRW | 0.0% |
| 2014 Q3 | 1.02 Billion KRW | 46.29% |
| 2014 Q2 | 700 Million KRW | 0.0% |
| 2014 Q4 | 1.6 Billion KRW | 56.49% |
| 2013 Q3 | 700 Million KRW | 0.0% |
| 2013 FY | 700 Million KRW | 0.0% |
| 2013 Q2 | 700 Million KRW | 0.0% |
| 2013 Q4 | 700 Million KRW | 0.0% |
| 2013 Q1 | - KRW | 0.0% |
| 2012 FY | - KRW | 0.0% |
| 2012 Q3 | - KRW | 0.0% |
| 2012 Q4 | - KRW | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 988.75 Million KRW | -1796.31% |
| CMG Pharmaceutical Co., Ltd. | 19.06 Billion KRW | 1.648% |
| Celltrion Pharm, Inc. | 4.33 Billion KRW | -332.691% |
| Huons Global Co., Ltd. | 66.94 Billion KRW | 71.991% |
| Enzychem Lifesciences Corporation | 1.02 Billion KRW | -1729.257% |
| Humedix Co., Ltd. | 1.75 Billion KRW | -968.169% |
| Boditech Med Inc. | 2.09 Billion KRW | -792.877% |
| EuBiologics Co., Ltd. | 2.8 Billion KRW | -569.639% |
| FutureChem Co.,Ltd | 2.61 Billion KRW | -615.7% |
| Huons Co., Ltd. | 58.35 Billion KRW | 67.867% |
| BNC Korea Co., Ltd. | 301.69 Million KRW | -6114.944% |
| AptaBio Therapeutics Inc. | 13.56 Billion KRW | -38.177% |